Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Alzheimer's vaccine trial aims to slow memory loss

NCT ID NCT07167966

Summary

This study is testing whether a vaccine called AADvac1 can slow the progression of Alzheimer's disease in its earliest stages. It will involve 375 adults aged 50-80 who have very early signs of the disease. The vaccine targets a protein called tau, and researchers will see if it works better alone or when combined with another Alzheimer's drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.